KNC Laboratories Co.,Ltd. (JP:6568)

:6568

6568

KNC Laboratories Co.,Ltd.

RESEARCH TOOLSreports

Want to see JP:6568 full AI Analyst Report?

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥997.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)2.89K

Market Cap

¥9.43B

Enterprise Value¥10.93B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)12.2

Beta0.51

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.98%

Share Statistics

EPS (TTM)85.36

Shares Outstanding7,779,900

10 Day Avg. Volume3,150

30 Day Avg. Volume2,890

Financial Highlights & Ratios

PEG Ratio3.29

Price to Book (P/B)0.67

Price to Sales (P/S)1.04

P/FCF Ratio-26.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.6

Revenue Forecast (FY)¥12.00B

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet / CapitalizationSustained equity growth and historically low debt-to-equity provide durable financial flexibility. This capitalization supports investment, absorbs cyclical margin pressure, and preserves capacity for strategic moves or distributions even if operating performance remains uneven.

Return To Revenue GrowthA clear rebound in top-line growth indicates recovering demand or successful commercial actions. Restored revenue momentum helps leverage fixed costs over time, underpins longer-term market position, and provides a base for restoring margins and earnings power if sustained.

Improving Operating Cash FlowMaterial improvement in operating cash flow signals operational recovery and better cash conversion from core activities. If maintained, stronger OCF can fund working capital and capex needs internally, reducing reliance on external financing and supporting durable business operations.

Bears Say

Compressed Profitability And MarginsMaterial margin deterioration undermines the company's earnings power and long-term return on invested capital. Persistently lower gross and operating margins reduce cover for fixed costs and investment, making it harder to rebuild earnings without sustained pricing or cost-structure improvements.

Negative Free Cash Flow Two Years RunningConsecutive negative free cash flow constrains financial flexibility, limiting ability to pay down debt, invest organically, or return capital. Over time, persistent negative FCF increases funding risk, potentially forcing higher leverage or reduced strategic investment.

Rising Debt In Last Two YearsAn increase in leverage while margins and FCF are under pressure raises the company’s financial vulnerability. Higher interest and principal obligations reduce resilience to shocks, may limit strategic optionality, and elevate the importance of restoring cash generation.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥997.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥9.43B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 68 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

KNC Laboratories Co.,Ltd. released its earnings results on May 14, 2026. The company reported ¥85.36 earnings per share for the quarter, beating the consensus estimate of N/A by ¥85.36.

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥17 which represents an annual dividend yield of 2.98%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

KNC Laboratories Co.,Ltd. reported an EPS of ¥85.36 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

KNC Laboratories Co., Ltd. engages in the research, development, and production solutions of organic chemicals in Japan. The company offers products for use in the pharmaceutical, electronic-chemical, agrochemical, energy, and environment fields. It offers support services for drugs and functional chemicals. The company was incorporated in 1985 and is headquartered in Kobe, Japan.